• Peters T. The relationship between LUTS and sexual function. Prostate cáncer and Prostatic diseases 4(1): S2-S6, 2001
• Pham H et al. 5-Reductase-catalyzed conversion of testosterone to dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids. J Ster Bioch Mol Biol 82:4-5:393-00, 2002
• Pienta K et al. Epidemiology of Prostate Cáncer: Molecular and environmental Clues. Urology 48 (5): 676-683. Nov 1996.
• Platz E, De Marzo A. Epidemiology of inflammation and prostate cáncer. J Urol 171(2) part 2 of 2: S36-S40, Feb 2004.
• Platz E, Willett W, Giovannucci E et al. Interrelation of energy intake, body size, and physical activity with prostate cáncer in a large prospective cohort study. Cáncer Res. 63(23):8542-8548, 1 Dec 2003
• Pollard M, Wolter W. Prevention of spontaneous prostate-related cáncer ¡n Lobund-Wistar rats by a soy protein ¡solate/isoflavone diet. Prostate 45(2):101-105, 2000
• Popa G, Hägele-Kaddour H, Walther C. Efficacy of a combined Sabal-urtica preparation ¡n the symptomatic treatment of benign prostatic hyperplasía. Results of a placebo-controlled double-blind study. MMW Fortschr Med 147(3):103-108 Oct 6, 2005
• Potenziani B JC. Enfermedades de la Próstata. Editorial Ateproca Caracas-Venezuela Mayo 2001
• Potenzlanl B JC et al. Disfunción Mlcclonal asociada a Hlperplasla Próstata Benigna. Rol del Detrusor en el éxito o fracaso de la cirugía próstata (revisión Clínica) Publicado en la Revista de la Facultad de Medicina de la Universidad Central de Venezuela 19 (3) 1995
• Potenzlanl B JC, Vargas J, Davlla H, et al. Doxazosln en el tratamiento de la Hlperplasla Próstata Benigna. Estudio Multlcentrlco Venezolano. Reporte Preliminar. Rev Ven Urol 43(1-2), Enero-Junio 1996
• Potenzlanl B JC et al . Trastornos Mlcclonales asociados a la Hlperplasla Próstata Benigna. papel del músculo detrusor en los resultados de la cirugía sobre la salida vesical (revisión clínica y experiencia personal) Rev Cent Médico de Caracas 42 (2): 101-106 Nov 1997
• Potenzlanl B JC. Vejiga Hlperactlva Editorial Ateproca 1999
• Potenzlanl B JC. (editor) Web Site www. urologia al dia. com
• Potenziani B JC. Vejiga Hlperactiva. Actualización 2005, CDrom Educación Médica Continua. Lithomedla 2007
• Potenziani B JC, Potenziani Pradella Silvia. Cuestionarios de Validación Diagnostica para diversas patologías urológicas. Rev Centro Médico 50(1) Nov 2005 (mención)
• Potenziani B JC. Capitulo Tres (III) del Consenso Nacional de Vejiga Hiperactlva. Tema Diagnostico de Vejiga Hlperactiva, Diagnostico diferencial, Test de Validación diagnostica para Vejiga Hiperactlva, Modelo de decisión (algoritmo) de Diagnostico en Vejiga Hlperactiva. Laboratorios Pfizer.CD de Educación Medica continua. Hotel Tamanaco-Caracas, Julio 2005
• Potenziani B JC. Suplemento Nutrlcional Prostatlco y Quimloprevención del Cáncer Prostético. Ch 21 Tópicos en Urología Ed. Ateproca 357-375, 2002
• Potenziani B JC. Fitoterapla. Tratamiento de la Vejiga Hiperactlva Capitulo XII Vejiga Hiperactlva. Edit Ateproca 265-270, 1999
• Potenziani B JC. Síndromes de Prostatitls, Avances en su enfoque. CD Educ Méd Cont. Bayer Health Care. Llthomedia 2005
• Potenziani B JC. Qulmioprevenclon del Cáncer Prostético.Capitulo II Cáncer de Próstata. Enfermedades de la Próstata. Editorial Ateproca 355-373, 2001
• Potenziani B JC. Tratamiento Farmacológico en hombres con síntomás urinarios bajos. CD Educ Méd Cont. Boehrlnger Ingelhelm. Lithomedla 2005
• Potenziani B JC. ¿Cómo reducir el riesgo de padecer un cáncer prostático? www. urologia al dia. com 2(1) Abril 2000
• Potenziani B JC. Análisis detallado de las recomendaciones urológicas másculinas con sugerencias en suplementaclón nutriclonal próstata. 3(2) del sitio WEB urologlaaldla.com . Editor J.C Potenziani
• Questionable Methods of Cáncer Management "Nutrltional" Theraples. Am Cáncer Society ¡n Cáncer. Cáncer Journal for Cllniclan. 43 (5): 309-319. Sep-Oct 1993.
• Ramón J et al. Dletary fat intake and prostate cáncer rlsk:a case control study ¡n Spain.Cáncer Causes Control ll(8):679-5, 2000
• Raynaud J, Cousse H, Martín P. Inhibltion of type 1 and type 2 5-reductase actlvity by free fatty aclds, active ¡ngredients of Permlxon® The Journal of Sterold Biochemlstry and Molecular Blology, 82:2-3:233-239, 2002
• Ríes L, Melbert D, Krapcho M et al. (eds). SEER Cáncer Statlstics Revlew. 1975-2004. National Cáncer Instltute. Bethesda, MD http://seer. cáncer. gov/csr/1975 2004/, based on November 2006 SEER data submisslon, posted to the SEER web site, 2007
• Rlngstad J, Jacobsen B, Tretll S. Serum selenlum concentration assoclated with rlsk of cáncer. J Clin Pathol 41:454-457,1988
• Rlngdal G et al. Does social support from famlly and frlends work as a buffer against reactlons to stressful Ufe events such as terminal cáncer? Palllative and Supportlve Care 5:61-69, 2007
• Ripoll E, Rama B, Webber M. Vltamin E enhances the chemotherapeutlc effects of adriamycln on human prostatic carcinoma cells ¡n vitro. J Urol 136(2): 529-531, 1986
• Rltch C, Wan R, Stephens L. Increased erythrocite membrane (EM) llnolelc acid levéis correlate wlth increased tumor volumen and Gleason Score. Abst #486 J Urol 175(4): 158 Aprll 2006
• Rlchardson M, Sanders T, Palmer J et al. Complementary/alternatlve medicine use in a comprehenslve cáncer center and the impllcations for oncology. J Clin Oncol 18 (13): 2505-14, 2000
• Rlchardson M, Straus S. Complementary and alternatlve medicine: opportunitles and challenges for cáncer management and research. Semln Oncol 29 (6): 531-45, 2002
• Robbers J, Speedle M, Tyler V. Pharmacognosy and pharmacoblotechnology. Baltlmore 1996 Willlams & Wilklns
• Roberts W, Platz E, Walsh P. Assoclation of clgarette smoking wlth extraprostatic prostate cáncer ¡n young men. Journal of Urology 169(2) 512-516, Feb 2003.
• Rodríguez C, McCullough M, Mondul A et al. Meat consumptlon among black and whlte men and risk of prostate cáncer ¡n the cáncer prevention study II Nutrltion Cohort. Canc Epld Biomarkers Prev 15;211-216,2006
• Roehrborn C, Boyle P, Nickel J et al. Efficacy and safety of a dual ¡nhibltor of 5-alpha-reductase types 1 and 2 (dutasterlde) in men wlth benign prostatic hyperplasía. Urology 60:434,2002
• Roehrborn C, Andrlole G, Bostwlck D, Civantos F, Epsteln J, et al.The effects of 5alpha-reductase ¡nhibltors on the natural hlstory, detection and gradlng of prostate cáncer: current state of knowledge. J Uroll74(6):2098-2104. Dec 2005
• Ross R, Bernsteln L, Lobo R et al. 5-alpha-reductase actlvity and risk of prostate cáncer among Japanese and US white and black males. Lancet 339(8798): 887-889, 1992
• Rose D, Connolly I. Omega-3 fatty aclds as cáncer chemopr agents. Pharmacol Ther 83:217-244, Sept 1999
• Rose D, Connolly J. Effects of fatty aclds and eicosanold synthesis ¡nhibltors on the growth of two human prostate cáncer cell Unes. The Prostate 18(3): 243-254, 1991.
• Rose D, Connolly J. Dletary fat, fatty acids and prostate cáncer. Llpids 27(10): 798-803, 1992.
• Rose D, Boyar A, Wynder E. Internatlonal comparlsons of mortallty rates for cáncer of the breast, ovary, prostate, and colon, and per caplta food consumption. Cáncer 58(11): 2363-2371, 1986.
• Rubba P,Manclni F, Gentlle M et al. The Medlterranean diet ¡n Italy: An update. World Rev Nutr Dlet. 97:85-113, 2007.
• Rugendorff E. Results of treatment wlth pollen extract ¡n chronic prostatltis and prostatodynla. BritJUrol 71:433-438, 1993
• Ruzek S. B. Towards a more Inclusive model of women's health. Am. J. Publlc Health 83:6-8, 1993
• Safarlnejad M. Urtica dioica for treatment of benign prostatic hyperplasía: a prospective, randomlzed, double-bllnd, placebo-controlled, crossover study. J Herb Pharmacother. 5(4):1-11, 2005
• Sánchez A, Antona J, Urrutla M. Geochemical prospectlon of cadmium ¡n a high ¡ncidence área of prostate cáncer, Sierra de Gata, Salamanca, Spaln. The Science of the Total Envlronment 116: 243-251, 1992.
• Saxe G, Hebert J, Carmody J et al. Can dlet in conjunctlon with stress reductlon affect the rate of increase ¡n prostate speciflc antigen after blochemical recurrence of prostate cáncer? J Urol 166,(6), 2202-2207, Dec 2001.
• Sakr W, Haas G, Cassln B et al. The frecuency of carcinoma and intraeplthellal neoplasla of the prostate in young male patlents. J Urol 150(2 Ptl): 379-85, Aug 1993.
• Sanders B. The prostate dlet cookbook. Harbor Press 2002.
• Sandfeldt L, Balley D, Hahn R. Blood loss durlng transurethral resectlon of the prostate after 3 months of treatment with flnasteride. Urology 58: 972-976,2001
• Saw palmetto berry. In: Blumenthal, M, Goldberg, A, Brlnckman, J, eds. Herbal Medicine: Expanded Commlssion E Monographs. Newton, MA: Llppincott Willlams & Wilklns; 335-340, 2000
• Schaid D, McDonnell S, Blute M. Evldence for autosomal domlnant inherltance of prostate cáncer. American Journal of Human Genetlcs 62(6): 1425-1438, 1998
• Schmidt L,Murlllo H,Tlndall D. Gene expresslon in prostate cáncer cells treated wlth the dual 5 alpha-reductase ¡nhibltor dutasteride. J Androl. 25(6): 944-953, Nov-Dec 2004
• Schmidt L et al. Inhlbitlon of fatty acid synthase actlvity ¡n prostate cáncer cells by Dutasteride. Prost 67(10):llll-20, May 2007
• Schmitz-Drager B et al. Chemopreventlon of prostate cáncer: Current status. Urologe A. 46(6):611-615, Jun 2007
• Schmltz-Drager, B.J., Eichholzer, M., Belche, B. and Ebert, T. Nutritlon and prostate cáncer. Urol. Int 67, 1-11, 2001
• Schoonen W et al. Alcohol consumption and risk of prostate cáncer in middle-aged men. Int J Cáncer 1;113(1):133-140, Jan 2005 Schroeder F. Chemo-endocrine prevention: recent achievements and potential. Ch 17 Progress and Controversies in Oncological
• Urology VI (Paciou VI) Renal, Bladder, Prostate and Testicular cáncer an update. Ed Kurth K, Mickisch G, Schroder F. The Parthenon
• Publishing Group 2000
• Schroeder F, Roobol M, Boeve E et al. Randomized double blind, Placebo-controlled crossover study in men with prostate cáncer
• and rising PSA: effectiveness of a dietary supplement. 48(6):922-931 Dec 2005
• Schulz V et al. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine 3rd ed. Berlin Ger: Springer-Verlag 1998:231 Scott L, Torkko K. Inflammation as a target for prostate cáncer chemoprevention: pathological and laboratory rationale. J Urol
• 171(2) part 2 of 2: S30-S35, Feb 2004.